Theravance Biopharma, Inc. (TBPH)

NASDAQ: TBPH · IEX Real-Time Price · USD

9.57

-0.11 (-1.14%)

At close: Jul 19, 2024, 4:00 PM

9.56

-0.01 (-0.10%)

Pre-market: Jul 20, 2024, 9:29 AM EDT

Theravance Biopharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2011
Net Income	-44.77	-55.19	872.13	-199.43	-278.02	-236.46	Upgrade
Depreciation & Amortization	6.03	6.15	7.71	8.59	8.05	9.67	Upgrade
Share-Based Compensation	23.58	25.37	39.73	62.06	62.98	60.45	Upgrade
Other Operating Activities	-1.64	-3.33	-1,106.56	-79.08	-43.41	-71.86	Upgrade
Operating Cash Flow	-16.8	-27	-186.99	-207.86	-250.4	-238.2	Upgrade
Capital Expenditures	-0.34	-0.98	1.29	-3.4	-6.55	-3.17	Upgrade
Acquisitions	0	0	2.71	0	0	5	Upgrade
Change in Investments	27.72	-31.72	54.87	127.89	17.27	-84.88	Upgrade
Other Investing Activities	-	-	1,095	-	-	-	Upgrade
Investing Cash Flow	27.38	-32.7	1,154	124.49	10.72	-83.05	Upgrade
Share Issuance / Repurchase	-144.41	-198.93	-131.48	102.59	135.23	3.44	Upgrade
Debt Issued / Paid	0	0	-631.6	-10.73	144.65	-2.15	Upgrade
Other Financing Activities	-	-	4.28	-	-16.8	-	Upgrade
Financing Cash Flow	-144.41	-198.93	-758.81	91.86	263.09	1.29	Upgrade
Net Cash Flow	-133.83	-258.63	208.21	8.5	23.4	-319.96	Upgrade
Free Cash Flow	-17.14	-27.97	-185.7	-211.26	-256.96	-241.37	Upgrade
Free Cash Flow Margin	-27.86%	-48.71%	-361.66%	-381.95%	-357.59%	-328.78%	Upgrade
Free Cash Flow Per Share	-0.35	-0.51	-2.52	-3.04	-4.12	-4.34	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).